论文部分内容阅读
目的:探讨阿托伐他汀强化治疗对急性冠脉综合征(ACS)患者的调脂效果。方法:选取广东省英德市人民医院于2015年1月至2016年12月收治的200例急性冠脉综合征患者,分为观察组和对照组各100例,观察组采取阿托伐他汀强化方案治疗(40 mg·次(-1),每日1次),对照组采取阿托伐他汀常规方案治疗(10 mg·次(-1),每日1次)。检测两组患者在治疗前、治疗4周后、治疗24周后的血脂水平,比较分析两种治疗方案的调脂效果。结果:两组患者治疗前血脂水平相似;治疗4周、12周后,两组患者血脂的各项指标都明显降低,观察组的总胆固醇(TC)含量、低密度脂蛋白含量(LDL)、高密度脂蛋白(HDL)、三酰甘油(TG)含量显著低于对照组,差异具有统计学意义(P<0.05)。治疗24周后随访两组患者预后情况,两组患者的血脂水平比较,差异均具有统计学意义(P<0.05),不良反应比较,差异无统计学意义(P>0.05)。结论:阿托伐他汀强化治疗与阿托伐他汀常规方案治疗相比,在ACS患者的调脂中效果更为显著,安全性好。
Objective: To investigate the lipid-lowering effect of atorvastatin on patients with acute coronary syndrome (ACS). Methods: A total of 200 patients with acute coronary syndrome admitted from January 2015 to December 2016 in Yingde Municipal People’s Hospital of Guangdong Province were divided into observation group (100 cases) and control group (100 cases). The observation group was treated with atorvastatin (40 mg · min -1, once a day). The control group was treated with atorvastatin (10 mg · min -1) once daily. Blood lipid levels of two groups before treatment, after 4 weeks of treatment and after 24 weeks of treatment were measured. The lipid-lowering effects of the two treatment regimens were compared. Results: Before treatment, the two groups of patients had similar blood lipid levels. After 4 weeks and 12 weeks of treatment, the indexes of blood lipid in both groups were significantly decreased. The levels of total cholesterol (TC), low density lipoprotein (LDL) The levels of HDL and triglyceride were significantly lower than those of the control group (P <0.05). After 24 weeks of treatment, the prognosis of the two groups were followed up. There was significant difference between the two groups in blood lipid levels (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions: Atorvastatin intensive therapy is more effective and safe than lipid lowering regimen in atherosclerosis in ACS patients compared with atorvastatin.